Symposium overview: Do environmental agents enter the brain via the olfactory mucosa to induce neurodegenerative diseases

Annals of the New York Academy of Sciences

Volumn 1170, Issue , 2009, Pages 610-614

  Doty, Richard L ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; APOLIPOPROTEIN E; CADMIUM; CHOLINERGIC RECEPTOR BLOCKING AGENT; DESIGNER DRUG; DOPAMINE RECEPTOR STIMULATING AGENT; IRON; LEVODOPA; MANGANESE; NATURAL RESISTANCE ASSOCIATED MACROPHAGE PROTEIN 2; ORGANIC ANION TRANSPORTER 1; PRION PROTEIN;

AIRBORNE PARTICLE; ALZHEIMER DISEASE; ANOSMIA; BRAIN; BRAIN REGION; CONFERENCE PAPER; CREUTZFELDT JAKOB DISEASE; DEGENERATIVE DISEASE; DIFFUSE LEWY BODY DISEASE; DISEASE MODEL; ENVIRONMENTAL FACTOR; HUMAN; MOTOR CONTROL; NEUROIMAGING; NEUROPATHOLOGY; NONHUMAN; OLFACTORY EPITHELIUM; OLFACTORY NERVE; OLFACTORY RECEPTOR; PARKINSON DISEASE; PARTICULATE MATTER; TRANSPORT KINETICS; VIRUS ENTRY; VIRUS TRANSMISSION;

EID: 68649123827     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2009.03926.x     Document Type: Conference Paper

References (45)

1. Brown, R.C., A.H. Lockwood & B.R. Sonawane. 2005. Neurodegenerative diseases: an overview of environmental risk factors. Environ. Health Perspect. 113:1250-1256.
2. Hudson, R. et al. 2006. Effect of air pollution on olfactory function in residents of Mexico City. Chem. Senses 31: 79-85.
3. Calderon-Garciduenas, L. et al. 2004. Brain inflammation and Alzheimer's-like pathology in individuals exposed to severe air pollution. Toxicol. Pathol. 32:650-658.
4. Antunes, M.B., R. Bowler & R.L. Doty. 2007. San- Francisco/Oakland Bay Bridge welder study: olfactory function. Neurology 69: 1278-1284.
5. Wright, J. 1914. A History of Laryngology and Rhinology. Lea & Febiger, Philadelphia, PA.
6. Flexner, S. & P.F. Clark. 1912. A note on the mode of infection in epidemic poliomyelitis. Proc. Soc. Exp. Biol. Med. 10: 1-2.
7. Brodie,M. & A.R. Elvidge. 1934. The portal of entry and transmission of the virus of poliomyelitis. Science79: 235-236.
8. Schultz, E.W. & L.P. Gebhardt. 1936. Prevention of intranasally inoculated poliomyelitis in monkeys by previous intranasal irrigation with chemical agents. Proc. Soc. Exp. Biol. Med. 34: 133-135.
9. Sabin, A.B. 1940. Olfactory bulbs in human poliomyelitis. Am. J. Dis. Child. 60: 1313-1318.
10. Sabin, A.B. & P.K. Olitsky. 1936. Influence of pathway of infection on pathology of olfactory bulbs in experimental poliomyelitis. Proc. Soc. Exp. Biol. Med.1936: 300-301.
11. Tisdall, F.F. et al. 1937. Zinc-sulphate nasal spray in the prophylaxis of poliomyelitis. Can. Public Health J.28: 523-543.
12. Doty, R.L. 2008. The olfactory vector hypothesis of neurodegenerative disease: is it viable? Ann. Neurol.63: 7-15. 12a.Genter, M.B., E.L. Kendig & M.D. Knutson. 2009. Uptake of materials from the nasal cavity into the blood and brain: are we finally beginning to understand these processes at the molecular level? Ann. N. Y. Acad. Sci. International Symposium on Olfaction and Taste. 1170: 623-628.
13. Johnson, R.T. & C.A. Mims. 1968. Pathogenesis for viral infections of nervous system. N. Engl. J. Med.278: 84-92.
14. Baker, H. & M.B.Genter. 2003.The olfactory system and the nasal mucosa as portals of entry of viruses, drugs, and other exogenous agents into the brain. In Handbook of Olfaction and Gustation. R.L. Doty, Ed.: 549-573. Marcel Dekker. New York, NY.
15. Baker, H. & R.F. Spencer. 1986. Transneuronal transport of peroxidase-conjugated wheat germ agglutinin (WGA-HRP) from the olfactory epithelium to the brain of the adult rat. Exp. Brain Res. 63: 461- 473.
16. Monath, T.P., C.B. Croop & A.K. Harrison. 1983. Mode of entry of a neurotropic virus into the central nervous system: reinvestigation of an old controversy. Lab. Invest. 48: 399-410.
17. Tjalve,H. & J. Henriksson. 1999. Uptake of metals in the brain via olfactory pathways. Neurotoxicology 20:181-195.
18. Henriksson, J. & H. Tjalve. 2000. Manganese taken up into the CNS via the olfactory pathway in rats affects astrocytes. Toxicol. Sci. 55: 392- 398.
19. Mancuso, M., A. Giovanetti & E.B. Brittebo. 1997. Effects of dichlobenil on ultrastructural morphology and cell replication in the mouse olfactory mucosa. Toxicol. Pathol. 25: 186-194.
20. Gillner, M. et al. 1987. Uptake and specific binding of 2,3,7,8-tetrachlorodibenzo-p-dioxin in the olfactory mucosa of mice and rats. Cancer Res. 47: 4150- 4159.
21. Kamel, F. & J.A. Hoppin. 2004. Association of pesticide exposure with neurologic dysfunction and disease. Environ. Health Perspect. 112: 950-958.
22. McLean, J.H. et al. 1993. Selective lesions of neural pathways following viral inoculation of the olfactory bulb. Exp. Neurol. 122: 209-222. 22a.Zanusso, G. et al. 2009. Different prion conformers target the olfactory pathway in sporadic Creutzfeldt- Jakob disease. Ann. N. Y. Acad. Sci. International Symposium on Olfaction and Taste. 1170: 637-643.
23. Zanusso, G. et al. 2003. Detection of pathologic prion protein in the olfactory epithelium in sporadic Creutzfeldt-Jakob disease. N. Engl. J. Med. 348: 711- 719.
24. Reuber, M. et al. 2001. New variant Creutzfeldt- Jakob disease presenting with loss of taste and smell. J. Neurol. Neurosurg. Psychiatry 71: 412-413.
25. Doty, R.L. 2003. Odor perception in neurodegenerative diseases. In Handbook of Olfaction and Gustation, 2nd ed. R.L. Doty, Ed.: 479-502. Marcel Dekker. New York, NY.
26. Doty, R.L., D.A. Deems & S. Stellar. 1988. Olfactory dysfunction in parkinsonism: a general deficit unrelated to neurologic signs, disease stage, or disease duration. Neurology 38: 1237-1244.
27. Graves, A.B. et al. 1999. Impaired olfaction as a marker for cognitive decline: interaction with apolipoprotein E ε4 status. Neurology 53: 1480-1487.
28. Ponsen, M.M. et al. 2004. Idiopathic hyposmia as a preclinical sign of Parkinson's disease. Ann. Neurol. 56:173-181.
29. Berendse,H.W. et al. 2001. Subclinical dopaminergic dysfunction in asymptomatic Parkinson's disease patients' relatives with a decreased sense of smell. Ann. Neurol. 50: 34-41.
30. Pearce, R.K., C.H. Hawkes & S.E. Daniel. 1995. The anterior olfactory nucleus in Parkinson's disease. Movement Disord. 10: 283-287.
31. Ohm,T.G. & H. Braak. 1987. Olfactory bulb changes in Alzheimer's disease. Acta Neuropathol. 73: 365- 369.
32. Attems, J. & K.A. Jellinger. 2006. Olfactory tau pathology in Alzheimer disease and mild cognitive impairment. Clin. Neuropathol. 25: 265-271.
33. Kovacs, T., N.J. Cairns & P.L. Lantos. 2001. Olfactory centres in Alzheimer's disease: olfactory bulb is involved in early Braak's stages. Neuroreport 12: 285- 288.
34. Kulkarni-Narla, A. et al. 1996. Manganese and copper-zinc superoxide dismutases in the human olfactory mucosa: increased immunoreactivity in Alzheimer's disease. Exp. Neurol. 140: 115-125.
35. Braak, H. et al. 2003. Idiopathic Parkinson's disease: possible routes by which vulnerable neuronal types may be subject to neuroinvasion by an unknown pathogen. J. Neural Transm. 110: 517-536. 35a.Hawkes, C.H., K. Del Tredici & H. Braak. 2009. Parkinson's disease: the dual hit theory revisited. Ann. N. Y. Acad. Sci. International Symposium on Olfaction and Taste. 1170: 615-622.
36. Hawkes, C.H., K. Del Tredici & H. Braak. 2007. Parkinson's disease: a dual hit hypothesis. Movement Disord. 22: S248.
37. Doty, R.L. et al. 1992. Lack of olfactory dysfunction in MPTP-induced parkinsonism. Ann. Neurol. 32: 97- 100.
38. Langston, J.W. et al. 1999. Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1-methyl-4-phenyl-1, 2,3,6-tetrahydropyridine exposure. Ann. Neurol. 46: 598-605.
39. Ross, G.W. et al. 2006. Association of olfactory dysfunction with incidental Lewy bodies. Movement Disord.21: 2062-2067. 39a. Prediger, R.D.S. et al. 2009. The risk is in the air: an intranasal MPTP rat model of Parkinson's disease. Ann. N. Y. Acad. Sci. International Symposium on Olfaction and Taste. 1170: 629-636.
40. Prediger, R.D. S. et al. 2006. The risk is in the air: intranasal administration of MPTP to rats reproducing clinical features of Parkinson's disease. Exp. Neurol.202: 391-403.
41. Giovanni, A. et al. 1994. Studies on species sensitivity to the dopaminergic neurotoxin 1-methyl-4-phenyl- 1,2,3,6-tetrahydropyridine. 1. Systemic administration. J. Pharmacol. Exp. Ther. 270: 1000-1007.
42. Giovanni, A., P.K. Sonsalla & R.E. Heikkila. 1994. Studies on species sensitivity to the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine.2. Central administration of 1-methyl- 4-phenylpyridinium. J. Pharmacol. Exp. Ther. 270:1008-1014.
43. Calderon-Garciduenas, L. et al. 2002. Air pollution and brain damage. Toxicol. Pathol. 30: 373- 389.
44. Paulsen, J.S. et al. 2008. Detection of Huntington's disease decades before diagnosis: the predict-HD study. J. Neurol. Neurosurg. Psychiatry 79: 874-880.
45. Forno, L.S. 1992. Neuropathologic features of Parkinsons, Huntingtons, and Alzheimers diseases. Ann. N. Y. Acad. Sci. 648: 6-16.